Ranibizumab-Eqrn (1 brand name, 1 dosage form, 1 route)
Available dosage forms: INJECTABLE.
Routes of administration: INJECTION.
Brand Names
- CIMERLI
Indications and Usage
CIMERLI is indicated for the treatment of patients with:
Adverse Reactions
The following adverse reactions are discussed in greater detail in other sections of the label: •Endophthalmitis and Retinal Detachments [see Warnings and Precautions (5.1)] •Increases in Intraocular Pressure [see Warnings and Precautions (5.2)] •Thromboembolic Events [see Warnings and Precautions (5.3)] •Fatal Events in patients with DME and DR at baseline [see Warnings and Precautions (5.4)]
Drug Interactions
Drug interaction studies have not been conducted with ranibizumab products. Ranibizumab intravitreal injection has been used adjunctively with PDT. Twelve of 105 (11%) patients with neovascular AMD developed serious intraocular inflammation; in 10 of the 12 patients, this occurred when ranibizumab was administered 7 days (± 2 days) after PDT.
Mechanism of Action
Ranibizumab products bind to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF110. VEGF-A has been shown to cause neovascularization and leakage in models of ocular angiogenesis and vascular occlusion and is thought to contribute to pathophysiology of neovascular AMD, mCNV, DR, DME and macular edema following RVO. The binding of ranibizumab products to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.
Overdosage
More concentrated doses as high as 2 mg ranibizumab in 0.05 mL have been administered to patients. No additional unexpected adverse reactions were seen.